Losartan Potassium Tablets USP recalled over manufacturing violations
- Recall date
- February 28, 2019
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Camber Pharmaceuticals Inc recalls Losartan Potassium Tablets USP, 25 mg, Rx only, a) 90 count (NDC 31722-700-90), b) 500 count (NDC 31722-700-05) and c)…
- Recall number
- D-1041-2019
- FDA classification
- Class II
- Brand / firm
- Camber Pharmaceuticals Inc
- Sold / distributed
- Nationwide
Why it was recalled
CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Losartan Potassium Tablets USP, 25 mg, Rx only, a) 90 count (NDC 31722-700-90), b) 500 count (NDC 31722-700-05) and c) 1000 count (NDC 31722-700-05) bottles, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 By: Hetero Hetero Labs Limited, Unit V, Polepally, Jadcherla, Mahaboob Nagar -509 301, India
Get recall alerts
Free email alert whenever Camber Pharmaceuticals Inc has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Camber Pharmaceuticals Inc